quarta-feira, 7 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 1, 2026

NVIDIA Unveils Vera, the CPU for Agents

View original at finance.yahoo.com
NVIDIA Unveils Vera, the CPU for Agents NVIDIA 1.8x Faster Than x86 Processors to Drive Diverse Workloads Across Industries, Generating More Data Center Token Revenue NVIDIA Vera CPU RackNVIDIA Vera is a new class of processor enabling 1.8x faster task completion compared with x86 CPUs.·GlobeNewswire Inc…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • NVIDIA Grace CPUs have achieved nearly 2.5 million shipments to date

    60% confidence

  • NVIDIA Vera CPU is now in full production

    60% confidence

  • AI agents will be the largest users of computing; Vera is the first CPU designed for that future, built to run agentic AI at hyperscale with extraordinary performance, efficiency and programmability

    60% confidence

  • The NYSE processes more than 1.1 trillion messages per day and will scale capacity while optimizing latency using NVIDIA Vera CPUs in collaboration with Redpanda and HPE

    60% confidence

  • NYSE's focus is to optimize the latency, throughput and reliability of its unrivaled infrastructure

    60% confidence

  • NVIDIA Vera CPU achieves 1.8x faster task completion compared with x86 CPUs

    60% confidence

  • Vera drives more data center token revenue compared to x86 alternatives

    60% confidence

  • Vera serves as the CPU powering standalone Vera servers, NVIDIA Vera Rubin systems, and Vera BlueField-4 STX AI storage platforms

    60% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
NVIDIA Unveils Vera, the CPU for Agents — Source | Via News | pt.VIA.NEWS